MiR-320a as a Potential Novel Circulating Biomarker of Arrhythmogenic CardioMyopathy

MiR-320a as a Potential Novel Circulating Biomarker of Arrhythmogenic CardioMyopathy

Abstract Diagnosis of Arrhythmogenic CardioMyopathy (ACM) is challenging and often late after disease onset. No circulating biomarkers are available to date. Given their involvement in several cardiovascular diseases, plasma microRNAs warranted investigation as potential non-invasive diagnostic tool...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elena Sommariva, Yuri D’Alessandra, Floriana Maria Farina, Michela Casella, Fabio Cattaneo, Valentina Catto, Mattia Chiesa, Ilaria Stadiotti, Silvia Brambilla, Antonio Dello Russo, Corrado Carbucicchio, Giulia Vettor, Daniela Riggio, Maria Teresa Sandri, Andrea Barbuti, Gianluca Vernillo, Manuela Muratori, Matteo Dal Ferro, Gianfranco Sinagra, Silvia Moimas, Mauro Giacca, Gualtiero Ivanoe Colombo, Giulio Pompilio, Claudio Tondo
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/e26e274e01914cf2a070af4986535dc0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Diagnosis of Arrhythmogenic CardioMyopathy (ACM) is challenging and often late after disease onset. No circulating biomarkers are available to date. Given their involvement in several cardiovascular diseases, plasma microRNAs warranted investigation as potential non-invasive diagnostic tools in ACM. We sought to identify circulating microRNAs differentially expressed in ACM with respect to Healthy Controls (HC) and Idiopathic Ventricular Tachycardia patients (IVT), often in differential diagnosis. ACM and HC subjects were screened for plasmatic expression of 377 microRNAs and validation was performed in 36 ACM, 53 HC, 21 IVT. Variable importance in data partition was estimated through Random Forest analysis and accuracy by Receiver Operating Curves. Plasmatic miR-320a showed 0.53 ± 0.04 fold expression difference in ACM vs. HC (p < 0.01). A similar trend was observed when comparing ACM (n = 13) and HC (n = 17) with athletic lifestyle, a ACM precipitating factor. Importantly, ACM patients miR-320a showed 0.78 ± 0.05 fold expression change vs. IVT (p = 0.03). When compared to non-invasive ACM diagnostic parameters, miR-320a ranked highly in discriminating ACM vs. IVT and it increased their accuracy. Finally, miR-320a expression did not correlate with ACM severity. Our data suggest that miR-320a may be considered a novel potential biomarker of ACM, specifically useful in ACM vs. IVT differentiation.

Ejemplares similares